NCT03213041View on ClinicalTrials.gov

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 14, 2017

Primary Completion Date

June 1, 2022

Study Completion Date

July 31, 2023

Conditions
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu NegativeProgesterone Receptor NegativeRecurrent Breast CarcinomaStage IV Breast CancerTriple-Negative Breast Carcinoma
Interventions
DRUG

Carboplatin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

60611

RECRUITING

Northwestern University, Chicago

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER